FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial. PMID 39532203 · Ann Oncol · 2025-Feb The study is a phase III randomized trial in oncology with a drug intervention, but the primary endpoint is organ preservation rate, a categorical outcome at a fixed time, not a time-to-event endpoint like OS, PFS, or DFS. No Kaplan-Meier curves or hazard ratios for survival or progression are reported or indicated as primary/secondary efficacy outcomes. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Ten-Year Outcome of a Randomized Trial: Cytoreduction and HIPEC with Mitomycin C Versus Oxaliplatin for Appendiceal Neoplasm with Peritoneal Dissemination. PMID 39531120 · Ann Surg Oncol · 2025-Feb The study is a randomized, prospective trial for a human malignancy with drug interventions (mitomycin C vs. oxaliplatin as part of HIPEC) and time-to-event endpoints (OS, PFS). However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata or abstract. The deterministic review flagged this as unclear. Therefore, is_eligible is set to false. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial. PMID 39528049 · Ann Oncol · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Incentivizing Tobacco Helpline Engagement in Persistent Poverty Counties: A Randomized Trial. PMID 39477130 · Am J Prev Med · 2025-Feb The record is a randomized trial in humans but is not an oncology (cancer) study. It evaluates a smoking cessation intervention (financial incentives) in a population with elevated cancer risk, but the primary outcomes are behavioral (coaching calls, abstinence rates) and not cancer-specific time-to-event efficacy endpoints. It lacks a drug intervention for cancer treatment. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. PMID 39477071 · Ann Oncol · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection. PMID 39472200 · Eur Urol · 2025-Feb The study is a randomized clinical trial in human oncology with time-to-event endpoints, but it does not involve a drug-containing intervention (comparing surgical techniques). The phase is not explicitly reported as Phase III/IIIb or Phase II/III in the provided metadata, and the signal indicates phase3 evidence is unclear. Therefore, it does not meet all required criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION). PMID 39446087 · J Urol · 2025-Feb The study is a randomized controlled trial, which is a key exclusion criterion. The primary endpoint is complete response at 3 months, not a time-to-event endpoint like OS, PFS, or DFS, and the paper does not present Kaplan-Meier curves or hazard ratios for a time-to-event outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial. PMID 39442040 · J Clin Oncol · 2025-Feb The record describes a final analysis of a randomized, drug-intervention trial in oncology (early breast cancer) with primary time-to-event efficacy endpoints (DFS, DDFS) and hazard ratios. Although the PubMed metadata did not explicitly list 'Phase III', the trial name 'DBCG 07-READ' and its context as a large, randomized, multi-center adjuvant trial strongly indicate a Phase III-equivalent definitive trial. The report provides formal results, not a protocol or review. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial. PMID 39433124 · Clin Microbiol Infect · 2025-Feb 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Prognostication of Surgically Resected Head and Neck Squamous Cell Carcinoma Using Pre-Therapy Neutrophil and Lymphocyte Counts. PMID 39415507 · Head Neck · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine. PMID 39400388 · Eur J Haematol · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol. PMID 39397266 · BJU Int · 2025-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial. PMID 39379238 · Eur Urol · 2025-Feb The trial is a randomized oncology study with a drug-containing adjuvant intervention. However, it lacks the required primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS), as the report explicitly states oncologic outcomes are immature and only reports treatment utilization and patient-reported outcomes. The phase is not explicitly stated as Phase III, and the design is a cluster-crossover trial focused on impact of testing, not a definitive efficacy comparison. Therefore, it does not meet the core eligibility criterion for a time-to-event endpoint in a Phase III/IIIb or definitive trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). PMID 39378386 · J Clin Oncol · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of up to 60 h of iv istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial. PMID 39375885 · ESC Heart Fail · 2025-Feb This is a protocol for a non-oncology (cardiogenic shock) Phase II/III trial. It lacks a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR) and does not report results. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Comparative Analysis of Electrosurgical Energy and Hemostatic Sealant for Hemostasis in Laparoscopic Ovarian Cystectomy: A Randomized Controlled Phase III Study. PMID 39374647 · J Minim Invasive Gynecol · 2025-Feb 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Real-world outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial. PMID 39324506 · BJU Int · 2025-Feb The study reports real-world outcomes for patients screened for the BRAVO trial but does not present formal results of the randomized trial comparison. The trial phase is not specified as Phase III/IIIb or Phase II/III, and the results are not for the planned randomized intervention comparison. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis. PMID 39293548 · Gastroenterology · 2025-Feb This is a phase 3 biomarker validation study for HCC detection in a diagnostic surveillance context. It is not a randomized trial and does not test a drug intervention or report time-to-event efficacy outcomes (e.g., OS, PFS). The primary endpoint is diagnostic performance (AUC, sensitivity, specificity). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Use of Water Sac Dilation in Resecting Parapharyngeal Space Benign Tumor via Transoral Approach. PMID 39289921 · Laryngoscope · 2025-Feb The record describes a randomized trial evaluating a surgical technique (water sac dilation) for a benign tumor. While oncology and human are true, and it is randomized with an original result, it lacks a drug-containing intervention and a time-to-event efficacy endpoint (OS, PFS, etc.), and the phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial. PMID 39143002 · Eur Urol Oncol · 2025-Feb The study is a randomized, controlled trial of a drug (cabazitaxel) in oncology (prostate cancer) with time-to-event endpoints (time to pain progression, time to opiate use, time to deterioration of FACT-P). However, the primary analysis was safety/toxicity-focused (as per the main CABASTY study referenced). This publication is an original result report, but its primary objective and analysis focus on patient-reported pain and health-related quality of life (HRQoL), which is a secondary/key secondary endpoint, not the primary efficacy endpoint (e.g., OS, PFS) for this oncology trial. Therefore, it does not meet the inclusion criterion of having a primary/key secondary time-to-event efficacy endpoint as the main focus of the report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Multicenter clinical trial on functional evaluation of transoral laser microsurgery for supraglottic laryngeal carcinomas. PMID 38885651 · Laryngorhinootologie · 2025-Feb The record fails multiple key eligibility criteria: it is not randomized, lacks a drug-containing intervention, and is a protocol/design paper without reported results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol. PMID 38755095 · Eur Urol Oncol · 2025-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED). PMID 38688766 · Eur Urol Oncol · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial. PMID 38584037 · Eur Urol Oncol · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison of two techniques of goal directed fluid therapy in elective neurosurgical patients - a randomized controlled study. PMID 36734344 · Br J Neurosurg · 2025-Feb The study is a randomized controlled trial in human oncology patients, but it is not a Phase III/IIIb or definitive trial, lacks a drug intervention (comparing fluid therapy techniques), and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). Primary and secondary endpoints are fluid volume, biochemical markers, and length of stay, not survival or time-to-event outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial. PMID 41590341 · Curr Oncol · 2025-Dec-31 The record describes a randomized, placebo-controlled trial in advanced ovarian cancer with a drug intervention and reports progression-free survival (PFS) as a primary efficacy endpoint. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the title, abstract, or provided metadata. Without explicit confirmation of the phase, the 'phase3_or_definitive' criterion cannot be met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Investigating the efficacy of electroacupuncture for postoperative ileus in patients with colorectal cancer: study protocol for a multicentre clinical trial with neuroimaging assessment. PMID 41475813 · BMJ Open · 2025-Dec-31 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Disparities in Non-Small Cell Lung Cancer (NSCLC) by Age, Sex, and Race: A Systematic Review and Meta-Analysis of Immune Checkpoint Inhibitor (ICI) Trials. PMID 41514637 · Cancers (Basel) · 2025-Dec-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Radical antegrade modular pancreatosplenectomy versus conventional left pancreatectomy for pancreatic cancer: study protocol for the multicentre randomized clinical RAMPS trial. PMID 41649934 · BJS Open · 2025-Dec-29 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Two-fraction Ultrahypofractionated Radiotherapy with focal BOost for intermediate-risk, localized prostate cancer (TURBO): study protocol of a phase II, randomized controlled clinical trial. PMID 41466435 · Trials · 2025-Dec-29 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Functional and cosmetic advantages of gasless endoscopic thyroidectomy in papillary thyroid carcinoma: a randomized trial. PMID 41466264 · World J Surg Oncol · 2025-Dec-29 The study is a randomized trial in human thyroid cancer but does not involve a drug-containing intervention and does not use a primary time-to-event efficacy endpoint. The primary endpoints are safety, lymph node counts, recurrence at 6 months, functional outcomes, and cosmetic satisfaction, which are not time-to-event efficacy measures like OS, PFS, or DFS. Additionally, the phase is not explicitly stated as Phase III or definitive. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Lobectomy-first versus lymphadenectomy-first on long-term survival for operable non-small cell lung cancer: protocol of LOFTY trial. PMID 41462323 · Trials · 2025-Dec-29 This is a protocol for a randomized trial in oncology with a time-to-event primary endpoint (disease-free survival). However, it is not an original result report, is a non-drug-only (surgical) intervention, and the phase is not explicitly stated as Phase III or equivalent in the metadata. The trial registration and abstract indicate it is a protocol without results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma. PMID 41461960 · J Cancer Res Clin Oncol · 2025-Dec-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison of the efficacy of TissuePatch™ versus no TissuePatch™ to seal pancreatic tissue surface for the prevention of pancreatic fistula after radical gastrectomy: study protocol for a prospective, single-center, randomized controlled trial. PMID 41456003 · Trials · 2025-Dec-28 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Immunomodulatory Effects of Multivitamin Complexes Containing Agaricus blazei in Patients Undergoing Curative Resection for Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Multicenter Pilot Trial. PMID 41595590 · Biomedicines · 2025-Dec-26 This is a randomized, double-blind, placebo-controlled pilot trial in NSCLC patients. However, it is not eligible because: 1) It is a pilot study, not explicitly Phase III or a definitive Phase II/III trial. 2) The intervention is a nutritional supplement (multivitamin complex), not a drug. 3) The primary endpoints are immunological and quality-of-life outcomes; no time-to-event efficacy endpoint (like OS or PFS) is reported or referenced. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The effect of perioperative multimodal rehabilitation on the frailty state of older people patients with frailty gastrointestinal surgery: a randomized controlled trial. PMID 41454251 · BMC Geriatr · 2025-Dec-26 Eligible record must include a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). This study is a randomized controlled trial in oncology (gastrointestinal tumors) but evaluates a non-drug intervention (multimodal rehabilitation program) and reports frailty status, functional, and quality-of-life outcomes, not time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life of patients undergoing active surveillance versus standard surgery for oesophageal cancer (SANO trial). PMID 41591326 · Br J Surg · 2025-Dec-24 The record is an original, randomized, oncology study in humans. However, it is excluded because: 1) The trial phase is not explicitly established as Phase III or II/III in the provided metadata; it is a stepped-wedge cluster-randomized trial. 2) The intervention is non-drug-only (active surveillance vs. surgery). 3) The primary endpoint is health-related quality of life, not a time-to-event efficacy endpoint. 4) The report is a quality-of-life analysis, not the primary efficacy report of the trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Three-dimensional printing model-assisted single-port laparoscopic multiple myomectomy: a randomized controlled trial. PMID 41444772 · Sci Rep · 2025-Dec-24 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies. PMID 41437135 · Prostate Cancer Prostatic Dis · 2025-Dec-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Pharmacogenomic, pharmacokinetic, and safety analysis of CYP3A4/CYP3A5 polymorphisms of midostaurin in patients with acute myeloid leukemia. PMID 41432755 · Eur J Clin Pharmacol · 2025-Dec-23 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML. PMID 41026969 · Blood Adv · 2025-Dec-23 The record describes a randomized Phase II/III trial (AML19) with drug intervention (midostaurin + gemtuzumab ozogamicin) and reports time-to-event efficacy endpoints (OS, EFS). However, the abstract and metadata do not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III; it is described as a 'UK National Cancer Research Institute AML19 trial' and the deterministic review flags phase3 evidence as unclear. Since the phase cannot be definitively established from the provided information, the record is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. PMID 40924923 · Blood Adv · 2025-Dec-23 The record describes a long-term extension study (LTE1) analyzing a subgroup of patients who transitioned from ibrutinib to zanubrutinib from the parent ASPEN Phase III trial. While the parent trial was a Phase III randomized trial with a drug intervention, this specific report is not the original primary result of that trial. Furthermore, it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR; the outcomes are safety and disease response rates. The analysis is explicitly noted as nonrandomized/ad hoc for this subgroup. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel. PMID 40862696 · Blood Adv · 2025-Dec-23 The study is excluded because it is not an oncology trial (it addresses a non-malignant hematologic condition) and its primary endpoint is quality of life, not a time-to-event efficacy measure. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel. PMID 40857358 · Blood Adv · 2025-Dec-23 The record describes a phase 3 trial of a gene-edited cell therapy for sickle cell disease, which is not an oncology/malignant neoplasm study. The primary focus is on health-related quality of life patient-reported outcomes, not a time-to-event efficacy endpoint. Additionally, the trial appears to be single-arm, not randomized. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Skin cancer and hyperthermia and radiotherapy - SAHARA: study protocol for a multicenter, two-arm, open-label, randomized controlled phase II non-inferiority trial. PMID 41430304 · Trials · 2025-Dec-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness analysis of datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer. PMID 41430249 · Cost Eff Resour Alloc · 2025-Dec-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The Efficacy and Safety of Traditional Chinese Medicine Qufenghuoxue Formula on Treating Peripheral Neuropathy Induced by Paclitaxel in Advanced Lung Cancer: A Randomized Clinical Trial. PMID 41428261 · Support Care Cancer · 2025-Dec-22 The study is an oncology RCT in humans with a drug intervention and is an original result report. However, it is excluded because the primary efficacy endpoint is not a time-to-event efficacy endpoint (like OS, PFS, DFS, etc.), but a proportion of CIPN relief and recovery time. The phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and the hazard ratio presented is for a secondary outcome (dose reduction/cessation), not for a primary key efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers after Large Vessel Occlusion Stroke: Results of a Prospective Randomized Open-Label Blinded Endpoint Trial. PMID 41428140 · Transl Stroke Res · 2025-Dec-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer. PMID 41186991 · JCI Insight · 2025-Dec-22 The record describes a preplanned biomarker analysis from the CARD trial (Phase IV per publication type). It is not the primary report of the Phase III trial results; it is a biomarker subgroup analysis. Therefore, it does not meet the inclusion criteria for a definitive Phase III trial primary result report with drug intervention and time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study. PMID 41423595 · Breast Cancer Res · 2025-Dec-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |